Related Experiment Video
Updated: Jul 19, 2026
07:34
Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique
Published on: December 15, 2023
Perspectives on neuroprotective stroke therapy.
1Department of Neurology, University of Münster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany. schabitz@uni-muenster.de
Biochemical Society Transactions
|November 1, 2006
Summary
Developing neuroprotective stroke therapies requires rigorous preclinical evaluation and strategic clinical trial design. Phase IIB and III trials should incorporate responder analysis, biomarkers, and outcome measures that detect relevant shifts for improved efficacy assessment.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- The development of neuroprotective stroke therapies has faced significant challenges and setbacks.
- Recent advancements and study results have revitalized the potential for effective neuroprotective treatments for stroke.
Purpose of the Study:
- To outline a comprehensive strategy for developing neuroprotective candidate drugs for stroke.
- To provide guidance on preclinical and clinical development phases, including trial design and endpoint selection.
Main Methods:
- Adherence to Stroke Therapy Academic Industry Roundtable (STAIR) criteria for preclinical evaluation.
- Phased clinical development starting with Phase IIA safety assessment.
- Incorporation of responder analysis, surrogate biomarkers, and Bayesian methodology in Phase IIB.
- Consideration of novel outcome measures for Phase III efficacy assessment.
Main Results:
- The review proposes a structured approach to navigate the complexities of neuroprotection drug development.
- Identifies key methodological considerations to enhance the probability of detecting therapeutic effects in clinical trials.
- Highlights the limitations of traditional dichotomized endpoints for neuroprotective agents.
Conclusions:
- Successful development of neuroprotective stroke therapies hinges on meticulous preclinical validation and adaptive clinical trial strategies.
- Shifting focus to detecting clinically relevant outcome measure shifts, rather than binary outcomes, is crucial for assessing efficacy.
- A refined approach incorporating advanced statistical and biomarker methodologies can improve the success rate of neuroprotective drug candidates.
Related Concept Videos
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...